This study aimed to rank cancers by the strength of relationship between comprehensive mRNA expression of the most harmful or protective genes and patient survival.
Introduction
In order to perform the most comprehensive research possible, we used TCGA dataset including clinical information, whole genome sequencing, exome sequencing, RNA-SEQ, small RNA-SEQ, bisulfite-SEQ, and reverse phase arrays to identify the pathways commonly altered in different cancers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
There are various approaches to cure cancers such as surgery, radiotherapy, immunotherapy or chemotherapy. Usually, most of chemotherapeutic methods have been the way to reduce or increase expression of protein or gene related to patient survival. However, while in some cancers, many biomarkers are efficient in treatment, in some other cancers, they are not. This research produces advantage of availability to provide scientific evidence of which cancers, comparing to another cancers, have significant relationship between clinical outcome and comprehensive mRNA expression level of prognostic genes. For the method, we formulated an indicator called prognostic score. The results of this study can be a kind of guide how to approach by cancers to develop cure for them.
Materials & Methods

Code and files
All of files and R codes generated for this study, including figures and tables can be downloaded from author's github page https://github.com/Minhyeong-1022/TCGA_mRNA-expression_survival_correlation_research. The scripts were run on a Samsung laptop 9 with i5 processor and 8GB of RAM running R 3.5.1 on Windows 10.
Construction of prognostic indicator model
To pull RNA-SEQ and clinical data into R source code, we used getFirehoseData function from R library named RTCGAToolbox, which pulls TCGA data from https://tcgadata.nci.nih.gov/tcga/, in September 2019. All of clinical follow up information were extracted from "clinical" files for each cancer, and only patient information whose clinical events occurred were included in this analysis. TCGA provides two types of mRNA expression data which are RNA-Seq and RNA-SeqV2. We used RNA-SeqV2 because it is the most recent version. "RNASeq2GeneNorm" files formed in RSEM which is one of mRNA expression reporting method and were outputted by the RSEM software [12] . For each cancer, only gene which has expression value greater than 1 included in this model. The prognostic score is determined by R2 and ratio of genes which have p-value of less than or equal to 0.01 generated from each term of cox model. R2 values are the Pearson correlation coefficient of R1 and cox coefficient. They were generated for each cancer. R1 values are Pearson correlation coefficient of patient specific survival days to death and mRNA expression values (RSEM) for each gene. They were generated for every gene. The information of TCGA dataset including number of genes selected by p-value generated from cox model are represented on Table. 1. Prognostic scores were generated for each cancer. The comprehensive prognostic indicator formula is represented below.
Information of multivariate cox model used in analysis
Gene specific cox coefficient and p-value for 16 cancers were generated in previous study, published in February 2016, by Jordan Anaya at University of Virginia [13, 14] . We used the data file "All genes, p-values, cox coefficients for each cancer", and it can be downloaded via https://peerj.com/articles/1499/#supp-1 .
Results
We decided to analyze using TCGA data which had enough number of patients with RNA- This study has purpose on ranking cancers by the sensitivities to prognostic gene expression level using specially formulated indicator called prognostic score. To achieve this multivariate Cox proportions hazards model [15] , which is a standard regression method to research clinical data [16] [17] [18] [19] was needed. Data table in previous study [13, 14] including gene specific cox coefficient and p-value for 16 cancers was used to minimize the efforts.
In few earlier studies, cox coefficient and p-value provided from each term of cox model were used to analyze how much mRNA expression of each gene influence on patient survival. There are significant deviations of patient survival patterns by expression level of genes which have extreme cox coefficient, and we can check this through Kaplan-Meier plot for all cancers (Fig.1d-g) . Patient survival in some cancer types are changed significantly by their gene expression level, but the patient survival in few another cancer type is not. It is because cancers vary in sensitivities to gene expression level. We calculated prognostic scores for all cancer types used in this study. Although the main factor of prognostic indicator is R2, not only R2 but also ratio of selected genes influences on patient survival. Cancers differ in prognostic score, and a bar-chart showing the rank displayed on Fig1. Expression levels of prognostic genes in top ranked cancer types are more influential on the patient clinical outcomes in those cancers, but such influences of bottom ranked are less than top ranked.
In the case of KIRC which has highest prognostic score among the 14 cancers, squared regression (R2) (Fig.1b) is more significant than R2 of OV ( Fig.1c ) which located bottom in the rank. KIRC and OV markedly differ in patient survival patterns by gene expression level. As following Fig1, KIRC is very sensitive to gene expression, but OV is not. And also, in the cases of another cancers, the prognostic sensitivities to gene expression level follow as the rank (Fig.1a ). Supplemental materials including Kaplan-Meier plots and scatter plots for other cancers can be downloaded via Git-hub page.
Discussion
In almost of cancers, mRNA expression level of protective or harmful genes filtered by cox coefficient influence on patient survival. But the performances differ by cancers. To rank cancers by how much prognostic gene expression levels influence on clinical outcome, specially formulated indicator called prognostic score was used in this study. In conclusion, it successfully predicted performances as the ranking. When researchers who develop medicine for cancers consider the cancer sensitivities to gene expression level, it can be a scientific evidence for their considering. For example, according to Fig1, while developing treatment for OV with chemotherapeutic method: reducing or increasing mRNA and protein level is not going to be efficient in high probability, research for KIRC is going to be efficient. 
